ExThera’s proprietary Seraph 100 Microbind Affinity Blood Filter (Seraph 100) is a first-of-its kind, CE Marked, technology designed to reduce bloodborne pathogens during bloodstream infections. Validated in preclinical studies and in a clinical trial in Europe, the device promises to address significant unmet needs for immediate treatment, even before the pathogen is identified.
Seraph’s broad-spectrum ability to reduce the pathogen bioburden without harming the treated blood gives it many potential clinical applications. The company has evaluated the therapeutic use of Seraph 100 in a dialysis-like extracorporeal circuit for treating patients with both drug-resistant and drug-susceptible bloodstream infections.

Watch viedo here